Articles tagged with Statins
A study published in PLoS ONE found that statin potency is a critical determinant of muscle-related side effects. Stronger statins like rosuvastatin were associated with higher rates of reported problems, highlighting the need for greater caution when prescribing these medications.
A meta-analysis of 16 statin trials and 7 fibrate trials found that statin therapy was associated with a 21% lower risk of pancreatitis. In contrast, fibrates showed no significant risk reduction. Lifestyle modifications remain important for improving lipid profiles in patients with hypertriglyceridemia.
A study published in The Lancet found that statin therapy can reduce cardiovascular disease risk, even among patients at high risk of developing diabetes. Patients with diabetes risk factors were 28% more likely to develop diabetes, but still saw a 39% reduced risk of cardiovascular illness and 17% lower mortality.
Researchers discovered that silencing miR-33 reduces bile transporters and improves liver toxicity caused by statins. This breakthrough may lead to treatment options for those with BRIC and statin side effects, including improved bile metabolism and reduced cholestasis.
A study published in the National Lipid Association Annual Scientific Sessions has shown that intensive cholesterol therapy involving a combination of drugs can be more effective over the long run than taking a single statin medication. After 20 years, patients on combination therapy had lower LDL and triglyceride levels, higher HDL, a...
A meta-analysis of 43,191 participants found statin therapy reduced recurrent cardiovascular events in both men and women. However, the benefits were not significant for women in terms of all-cause mortality or stroke risk. The study highlights the need for more female participants in cardiovascular prevention trials.
Researchers found that adding certain apolipoproteins and lipoproteins to risk scores improved cardiovascular disease prediction in individuals without known CVD. However, the addition of these markers did not improve discrimination beyond conventional risk factors, and the clinical benefits remain uncertain.
Researchers found that individuals taking statin cholesterol-lowering drugs are more likely to experience decreased energy and fatigue upon exertion. The study, which included over 1,000 adults, suggests that these side effects should be taken into account when prescribing statins.
Studies show that statin therapy may be safe and beneficial for individuals with cirrhosis, reducing heart disease risk. Additionally, adding telaprevir to a drug regimen improves quality of life in patients with chronic hepatitis C. Probiotic dairy consumption also affects brain regions controlling emotional arousal.
A new study found that people who used statins before and during their hospital stay were more likely to return home than those who did not, with 57% of statin users returning home compared to 47% of non-users. Statin use was also associated with a lower risk of dying in the hospital.
Researchers found that statin users had less prostate growth compared to non-users, regardless of whether they took dutasteride or a placebo. The effect was relatively small and tapered off after two years.
A study presented at Heart Failure Congress 2012 found that statin therapy prevents cancer and reduces death from all causes in heart transplant recipients. Cancer is the leading cause of death late after heart transplantation, with skin cancer being particularly common.
A meta-analysis confirms statins reduce major vascular events by 21% in those with low risk of vascular disease. Statin therapy outweighs known side effects, suggesting current guidelines may need revision.
Patients with rheumatoid arthritis who discontinue statin therapy are at increased risk of cardiovascular disease and other causes. A population-based study found that RA patients should be advised to maintain medication compliance to reduce mortality risk.
A meta-analysis found that non-HDL-C levels are strongly associated with the risk of major cardiovascular events in patients taking statins, more so than LDL-C. Non-HDL-C was also shown to explain a larger proportion of the atheroprotective effect of statin therapy.
A novel monoclonal antibody, SAR236553/REGN727, has been shown to dramatically lower circulating LDL cholesterol by 40-72% in patients, providing a potential new treatment option for those resistant to statins. The study's results demonstrate a dose-response effect, with higher doses resulting in greater reductions in LDL cholesterol.
A study found that patients who viewed images of their coronary artery calcium scores were more likely to take statins as directed and lose weight, with compliance increasing as disease severity increased. This suggests that visualizing the extent of cardiovascular disease can motivate patients to adhere to recommended therapies.
A randomized trial found that rosuvastatin reduced the incidence of pneumonia by 17.8% compared to placebo. The absolute risk reduction was small, and the effects on infection may be greater in other settings.
A study published in Archives of Neurology found a possible association between statin use and reduced risk of developing Parkinson's disease, particularly among younger individuals. The research included over 38,000 men and women and followed them for 12 years, documenting 644 incident PD cases.
Patients with heart disease who took cholesterol-lowering statins were significantly less likely to develop depression than those who did not. Statin users experienced a 38% lower risk of developing depression compared to non-statin users.
Statins, cholesterol-lowering medications, have been shown to inhibit the growth of breast cancer cells with mutant p53 genes. By targeting a specific pathway involved in cell proliferation, statins may be effective in treating these types of tumors.
A recent study published by JAMA Network found that statin use in postmenopausal women is associated with an increased risk of developing diabetes. The study, which analyzed data from the Women's Health Initiative, included over 153,000 women and found that statin use was linked to a higher risk of new-onset diabetes.
A large cohort study found that statin use was associated with an increased risk of interstitial lung abnormalities (ILA) in smokers, with a 60% higher odds of ILA compared to non-statins users. Statins also exacerbated lung fibrosis in mice and enhanced Nlrp3-inflammasome activation.
Researchers discovered that statin therapy can reduce blood clotting by targeting the expression of inducible tissue factor, a molecule that triggers abnormal clotting. Elevated levels of oxidized LDL induce tissue factor, which contributes to the formation of an occlusive thrombus after plaque rupture.
A new study found that statin use reduced mortality among hospitalized influenza patients by almost twice as much. Researchers are exploring combining statins with antiviral drugs for better treatment.
An observational study found that statin use was associated with a decreased risk of dying among hospitalized patients with laboratory-confirmed influenza. Researchers also noted the potential benefits of randomized controlled trials to further examine the effectiveness of statins for influenza treatment.
Researchers discovered how statins promote the breakdown of plaque by activating a cell surface receptor, forcing macrophages out of plaque. The study supports clinical findings that high-dose statins reduce cholesterol levels and plaque amount in arteries.
Long-term follow-up of statin trial shows benefits persisted after treatment cessation, with no increase in cancer incidence or non-vascular mortality. Statins are deemed safe for long-term use in reducing vascular disease risk.
A new study found that evacetrapib, a CETP inhibitor, significantly increased HDL-C levels and decreased LDL-C levels in patients with sub-optimal lipid profiles. The medication was effective when used alone or in combination with statin medications, producing dose-dependent increases in HDL-C.
Researchers discovered three bile acids produced by gut bacteria that influence statin effectiveness in lowering cholesterol. This finding supports the role of the gut microbiome in drug response and metabolism, opening new avenues for targeted therapies and diagnostics.
Researchers at Mount Sinai School of Medicine found that $6.7 billion was spent on unnecessary tests or medications, with brand-name statins accounting for 86% of the cost. Excess spending included blood work, bone density scans, and antibiotic prescriptions.
A retrospective study of 17,872 patients found no association between statin use and increased risk of intracerebral hemorrhage after ischemic stroke. The study's results contradict previous findings and suggest that current treatment guidelines recommending statin therapy for most patients with a history of ischemic stroke may be safe.
A new analysis of the ASCOT trial has found that statins prescribed to patients in 2003 still lower mortality rates from infections and respiratory illnesses eight years later. The study also shows no significant difference in cancer deaths, but reduced cardiovascular disease fatalities.
A global study found that 60% of individuals with heart disease and up to half of stroke patients are not taking four effective drug types, with underuse highest in low-income countries. The study suggests improvements in drug use could substantially reduce global cardiovascular disease within years.
The new guidelines aim to improve lipid management in patients with cardiovascular disease. Lifestyle interventions, such as diet and exercise, should be the first step in managing lipids.
Research suggests that statin cholesterol-lowering medications can lower stroke risk in patients with ischemic strokes. However, patients with hemorrhagic strokes or certain high-risk profiles may not benefit from statins. Further research is needed to understand the optimal use of statins in these cases.
A study of over 2,000 people found that high levels of coronary calcium were a better predictor of heart attack and stroke risk than C-reactive protein. The research suggests that statin medication may be unnecessary for some individuals with normal LDL cholesterol levels and low C-reactive protein levels.
A new study suggests that coronary artery calcium (CAC) is a more accurate predictor of heart attacks and strokes than C-reactive protein (CRP) in healthy adults. High CAC scores are associated with a fourfold increased risk of cardiovascular disease, while low scores indicate an extremely low risk of events. Statin treatment may be mo...
A commentary in New England Journal of Medicine suggests fibrates do not lower heart risk in diabetic patients taking statins; doctors recommend prescription only to high-risk patients after optimal LDL control achieved
Cholesterol-lowering statin drugs were found to reduce the risk of second strokes by 77% in young adults who experienced a first ischemic stroke. The study, published in Neurology, suggests that these medications should be considered for treatment even when the cause of the stroke is unknown.
A recent study by Kaiser Permanente found that patients with new statin prescriptions obtained through mail-order pharmacies showed improved cholesterol control in the first 3-15 months. This is compared to those who only used their local pharmacy, where 74.2% achieved target cholesterol levels.
A new analysis of a clinical trial found that an experimental drug, torcetrapib, can improve blood sugar control in people with type 2 diabetes who are taking cholesterol-lowering drugs. The study showed that torcetrapib increased levels of 'good' cholesterol and improved glucose measurements.
The new guidelines emphasize the importance of comprehensive lipid control, with a focus on lifestyle interventions as the first step. In high-risk patients, targeted treatments such as statins and combination therapies are recommended to achieve optimal LDL cholesterol levels and reduce cardiovascular risk.
A meta-analysis of 32,752 participants found that intensive-dose statin therapy was associated with a higher incidence of new-onset diabetes compared to moderate-dose therapy. In contrast, intensive statin therapy reduced the number of major cardiovascular events.
The European Society of Cardiology is urging more research into vulnerable plaques and their stabilization. Studies have shown that therapies like statins and anti-platelet drugs can reduce cardiovascular events, while imaging tools and biomarkers may help identify at-risk patients.
Researchers found type 2 diabetes increased the risk of recurrent stroke and cardiovascular events, while metabolic syndrome was not associated with these risks. Statin treatment reduced the risk in participants with type 2 diabetes or metabolic syndrome.
A Penn-led study has identified common clinical activities where changes in practice could lead to higher quality care and better use of finite clinical resources. The 'Top 5' list for internal medicine includes practices such as not overimaging, not overscreening, and using generic statins.
A study published in Archives of Internal Medicine found that low-risk patients who underwent coronary computed tomographic angiography (CCTA) screening were more likely to receive medications and undergo additional testing. However, their cardiac event rates did not significantly differ from those who did not undergo screening.
A new study from North Carolina State University reveals that most high-risk patients do not adhere to prescribed statin treatment, despite the significant benefits of taking these medications. The study found that only 48% of patients take their statins as prescribed after one year, and this number drops to 27% after 10 years.
Researchers found that simvastatin significantly reduces lung damage and inflammation in severe abdominal sepsis. The study suggests statins may be of clinical value for patients with severe abdominal infections.
Researchers found that patients already taking statins experienced greater restoration of blood flow to the brain compared to those not on statins. This could lead to better outcomes for stroke patients and potentially improved recovery rates.
Researchers investigate whether statins can prevent pre-eclampsia by targeting an enzyme that suppresses two proteins linked to the condition. The study, funded by the Medical Research Council, aims to test the effectiveness of statins in reducing blood pressure risks for pregnant women diagnosed with very early-onset pre-eclampsia.
A population-based retrospective study found that taking statins before major elective surgery reduces potentially serious kidney complications and premature death. Statin use was associated with lower incidence of acute kidney injury, dialysis need, and mortality.
A study by the London School of Hygiene and Tropical Medicine found that statin users had a 33% lower risk of death from pneumonia compared to non-statin users. This protective effect was observed among patients who were already taking statins when they developed pneumonia.
The use of fibrates has increased steadily in the United States over the past decade, driven by a strong preference for brand-name products. Despite negative trial results, fibrates are still prescribed in high numbers, despite uncertain clinical benefits.
Researchers found that statin atorvastatin reduced CD38 and HLA-DR levels on T cells in HIV-infected patients, suggesting potential benefits in disease management. The study's findings support exploring the role of statins as an anti-inflammatory therapy for HIV.
Researchers analyzed over 20,000 patients who took simvastatin and found that statins reduced major vascular events by the same amount regardless of CRP levels. The results suggest that baseline CRP concentration or inflammation status does not impact the benefits of statin therapy.
A new Cochrane Systematic Review questions the benefits of statins in people with no previous history of heart disease. Statin use should be prescribed with caution in those at low risk of cardiovascular disease, as the absolute numbers of people who benefit are lower.
A computer decision model suggests that statin therapy may increase the risk of recurrent intracerebral hemorrhage in patients with a history of brain hemorrhage. Statins may not provide sufficient benefits to outweigh these risks for this patient group, particularly those with lobar intracerebral hemorrhage.
Researchers have described the first functioning 'lipidome' of a mouse macrophage, a white blood cell, providing new insights into how lipids interact and change over time in response to bacterial stimuli. The study sheds light on the crucial role of lipid molecules in inflammation and disease.